Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 7-(4-(4-(1-benzothiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2(1h)-one
2. Rexulti
1. 913611-97-9
2. Opc-34712
3. Rexulti
4. 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2(1h)-one
5. Opc 34712
6. 2j3ybm1k8c
7. 7-(4-(4-(1-benzothiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2(1h)-one
8. 7-[4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy]-1h-quinolin-2-one
9. Brexpiprazole [usan]
10. Unii-2j3ybm1k8c
11. Brexpiprazole [usan:inn]
12. Rxulti
13. Rexulti (tn)
14. Brexpiprazole.2h2o
15. Brexpiprazole-[d8]
16. Brexpiprazole [mi]
17. Brexpiprazole [inn]
18. Brexpiprazole [jan]
19. Brexpiprazole(opc34712)
20. Brexpiprazole; Opc-34712
21. Brexpiprazole [who-dd]
22. Gtpl7672
23. Schembl1037592
24. Brexpiprazole (jan/usan/inn)
25. Chembl2105760
26. Schembl14772509
27. Amy6914
28. Dtxsid40238527
29. Chebi:134716
30. Hms3885p12
31. Brexpiprazole [orange Book]
32. Bcp10218
33. Bcp24077
34. Ex-a2639
35. Opc34712
36. Mfcd27987920
37. S4639
38. Zinc84758479
39. Akos025291100
40. Akos037515802
41. Ccg-269055
42. Db09128
43. Sb16735
44. Ncgc00378574-01
45. Ncgc00378574-02
46. Ac-30404
47. As-56467
48. Da-35913
49. Hy-15780
50. Ft-0712292
51. A13527
52. D10309
53. Q2924764
54. 2(1h)-quinolinone, 7-(4-(4-benzo(b)thien-4-yl-1-piperazinyl)butoxy)-
55. 7-[4-(4-benzo[b]thien-4-yl-1-piperazinyl)butoxy]- 2(1h)-quinolinone
56. 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1h-quinolin-2-one
57. 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1h-quinolin-2-one
58. 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-1h-quinolin-2-one
Molecular Weight | 433.6 g/mol |
---|---|
Molecular Formula | C25H27N3O2S |
XLogP3 | 4.7 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 7 |
Exact Mass | 433.18239829 g/mol |
Monoisotopic Mass | 433.18239829 g/mol |
Topological Polar Surface Area | 73 Ų |
Heavy Atom Count | 31 |
Formal Charge | 0 |
Complexity | 636 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
As an adjunctive treatment of major depressive disorder (MDD) and for treatment of schizophrenia.
FDA Label
Treatment of schizophrenia.
Dopamine Agonists
Drugs that bind to and activate dopamine receptors. (See all compounds classified as Dopamine Agonists.)
Serotonin Agents
Drugs used for their effects on serotonergic systems. Among these are drugs that affect serotonin receptors, the life cycle of serotonin, and the survival of serotonergic neurons. (See all compounds classified as Serotonin Agents.)
N05AX16
N - Nervous system
N05 - Psycholeptics
N05A - Antipsychotics
N05AX - Other antipsychotics
N05AX16 - Brexpiprazole
Absorption
Brexpiprazole reaches peak plasma concentration within 4 hours of administration, and steady state occurs within 10-12 days of dosing. Oral bioavailability is 95%, and can be administered with or without food.
Route of Elimination
Approximately 25% urinary and 46% fecal excretion. <1% and ~14% of the unchanged drug was recovered in the urine and feces, respectively.
Volume of Distribution
Intravenous volume of distribution is 1.56L/kg.
Clearance
19.8mL/h/kg
Metabolized mainly by CYP3A4 and CYP2D6 enzymes into its major metabolite, DM-3411. DM-3411 is not considered to contribute any therapeutic effect.
Brexpiprazole and its major metabolite, DM-3411 have half lives of 91 and 96 hours respectively.
Although the mechanism of action of brexpiprazole in the treatment of MDD and schizophrenia is unclear, the efficacy of brexpiprazole may be attributed to partial agonist activity at serotonin 1A and dopamine D2 receptors, and antagonist activity at serotonin 2A receptors.
Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 32347
Submission : 2017-12-21
Status : Active
Type : II
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : Complete
Rev. Date : 2019-04-16
Pay. Date : 2019-03-22
DMF Number : 33704
Submission : 2019-03-20
Status : Active
Type : II
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
GDUFA
DMF Review : Complete
Rev. Date : 2019-03-18
Pay. Date : 2018-10-01
DMF Number : 33450
Submission : 2019-02-12
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2019-06-07
Pay. Date : 2019-04-15
DMF Number : 33122
Submission : 2018-09-29
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2018-07-10
Pay. Date : 2018-03-27
DMF Number : 32532
Submission : 2018-06-04
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 32995
Submission : 2018-12-31
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2019-05-02
Pay. Date : 2019-02-07
DMF Number : 33421
Submission : 2019-02-07
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2019-04-12
Pay. Date : 2019-01-28
DMF Number : 32142
Submission : 2017-10-30
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33231
Submission : 2018-10-19
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2019-02-27
Pay. Date : 2018-12-20
DMF Number : 33437
Submission : 2019-01-02
Status : Active
Type : II
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Rxulti (brexpiprazole) is an atypical antipsychotic, small molecule drug candidate. It is indicated for the treatment of schizophrenia in adolescents aged 13 years and older.
Lead Product(s): Brexpiprazole
Therapeutic Area: Psychiatry/Psychology Brand Name: Rxulti
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 17, 2025
Lead Product(s) : Brexpiprazole
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Rxulti® Approved in EU for Treating Schizophrenia in Adolescents
Details : Rxulti (brexpiprazole) is an atypical antipsychotic, small molecule drug candidate. It is indicated for the treatment of schizophrenia in adolescents aged 13 years and older.
Product Name : Rxulti
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 17, 2025
Details:
Brexpiprazole is a 5-HT2A receptor inhibitor and 5-HT1A/D2 receptor partial agonist. It is approved for the treatment of Major Depressive Disorder.
Lead Product(s): Brexpiprazole
Therapeutic Area: Psychiatry/Psychology Brand Name: Rexulti
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 15, 2025
Lead Product(s) : Brexpiprazole
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Alembic Pharma Gets USFDA Final Approval for Brexpiprazole Tablets
Details : Brexpiprazole is a 5-HT2A receptor inhibitor and 5-HT1A/D2 receptor partial agonist. It is approved for the treatment of Major Depressive Disorder.
Product Name : Rexulti
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 15, 2025
Details:
Rexulti (brexpiprazole) 5-HT2A receptor, is being evaluated in combination with sertraline in late-stage clinical trials with adult patients for the treatment of post-traumatic stress disorder.
Lead Product(s): Brexpiprazole,Sertraline Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Rexulti
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: H. Lundbeck AS
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 04, 2024
Lead Product(s) : Brexpiprazole,Sertraline Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : H. Lundbeck AS
Deal Size : Inapplicable
Deal Type : Inapplicable
Otsuka and Lundbeck Submit sNDA for FDA Review of Brexpiprazole and Sertraline Combination
Details : Rexulti (brexpiprazole) 5-HT2A receptor, is being evaluated in combination with sertraline in late-stage clinical trials with adult patients for the treatment of post-traumatic stress disorder.
Product Name : Rexulti
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 04, 2024
Details:
Rexulti (brexpiprazole) is an partial agonist activity at serotonin 5-HT1A, which is being investigated in combination therapy with sertraline for the treatment of post-traumatic stress disorder.
Lead Product(s): Brexpiprazole,Sertraline Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Rexulti
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: H. Lundbeck AS
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 04, 2024
Lead Product(s) : Brexpiprazole,Sertraline Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : H. Lundbeck AS
Deal Size : Inapplicable
Deal Type : Inapplicable
Otsuka and Lundbeck Submit sNDA for FDA Review of Brexpiprazole
Details : Rexulti (brexpiprazole) is an partial agonist activity at serotonin 5-HT1A, which is being investigated in combination therapy with sertraline for the treatment of post-traumatic stress disorder.
Product Name : Rexulti
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 04, 2024
Details:
Rexulti (brexpiprazole) is an partial agonist of serotonin 5-HT1A, which is being investigated in combination therapy with sertraline for the treatment of post-traumatic stress disorder (PTSD).
Lead Product(s): Brexpiprazole,Sertraline Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Rexulti
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: H. Lundbeck AS
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 25, 2024
Lead Product(s) : Brexpiprazole,Sertraline Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : H. Lundbeck AS
Deal Size : Inapplicable
Deal Type : Inapplicable
Otsuka and Lundbeck Announce FDA Acceptance for Brexpiprazole in PTSD Treatment
Details : Rexulti (brexpiprazole) is an partial agonist of serotonin 5-HT1A, which is being investigated in combination therapy with sertraline for the treatment of post-traumatic stress disorder (PTSD).
Product Name : Rexulti
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 25, 2024
Details:
Rexulti (brexpiprazole) is a 5-HT2A receptor inhibitor and 5-HT1A/D2 receptor partial agonist. It is approved for the treatment of Major Depressive Disorder.
Lead Product(s): Brexpiprazole
Therapeutic Area: Psychiatry/Psychology Brand Name: Rexulti
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 22, 2023
Lead Product(s) : Brexpiprazole
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rexulti (brexpiprazole) is a 5-HT2A receptor inhibitor and 5-HT1A/D2 receptor partial agonist. It is approved for the treatment of Major Depressive Disorder.
Product Name : Rexulti
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 22, 2023
Details:
Rexulti (brexpiprazole) is an atypical antipsychotic, is the first and only pharmacological treatment approved in the U.S. for agitation associated with dementia due to Alzheimer’s disease.
Lead Product(s): Brexpiprazole
Therapeutic Area: Psychiatry/Psychology Brand Name: Rexulti
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: H. Lundbeck AS
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 05, 2023
Lead Product(s) : Brexpiprazole
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : H. Lundbeck AS
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rexulti (brexpiprazole) is an atypical antipsychotic, is the first and only pharmacological treatment approved in the U.S. for agitation associated with dementia due to Alzheimer’s disease.
Product Name : Rexulti
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 05, 2023
Details:
Rexulti (brexpiprazole) is an atypical antipsychotic & serotonin 5HT2a inhibitor. It is the first and only pharmacological treatment approved in the U.S. for agitation associated with dementia due to Alzheimer’s disease.
Lead Product(s): Brexpiprazole
Therapeutic Area: Neurology Brand Name: Rexulti
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 31, 2023
Lead Product(s) : Brexpiprazole
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rexulti (brexpiprazole) is an atypical antipsychotic & serotonin 5HT2a inhibitor. It is the first and only pharmacological treatment approved in the U.S. for agitation associated with dementia due to Alzheimer’s disease.
Product Name : Rexulti
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 31, 2023
Details:
Brexpiprazole's action is mediated through a combination of partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, and antagonist activity at serotonin 5-HT2A receptors. It is indicated for the treatment if treatment of MDD or schizophrenia.
Lead Product(s): Brexpiprazole
Therapeutic Area: Psychiatry/Psychology Brand Name: Brexpiprazole-Generic
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 03, 2023
Lead Product(s) : Brexpiprazole
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Brexpiprazole's action is mediated through a combination of partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, and antagonist activity at serotonin 5-HT2A receptors. It is indicated for the treatment if treatment of MDD or schizophre...
Product Name : Brexpiprazole-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 03, 2023
Details:
Rexulti (brexpiprazole) is an partial agonist activity at serotonin 5-HT1A, which is investigated in combination therapy with sertraline for the treatment of post-traumatic stress disorder (PTSD).
Lead Product(s): Brexpiprazole,Sertraline Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Rexulti
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: H. Lundbeck AS
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 09, 2023
Lead Product(s) : Brexpiprazole,Sertraline Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : H. Lundbeck AS
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rexulti (brexpiprazole) is an partial agonist activity at serotonin 5-HT1A, which is investigated in combination therapy with sertraline for the treatment of post-traumatic stress disorder (PTSD).
Product Name : Rexulti
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 09, 2023
Regulatory Info :
Registration Country : Switzerland
Brand Name : Rexulti
Dosage Form : Filmtabl
Dosage Strength : 0.5mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Brand Name : Rexulti
Dosage Form : Filmtabl
Dosage Strength : 1mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Brand Name : Rexulti
Dosage Form : Filmtabl
Dosage Strength : 1mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Brand Name : Rexulti
Dosage Form : Filmtabl
Dosage Strength : 2mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Brand Name : Rexulti
Dosage Form : Filmtabl
Dosage Strength : 3mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Brand Name : Rexulti
Dosage Form : Filmtabl
Dosage Strength : 4mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
95
PharmaCompass offers a list of Brexpiprazole API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Brexpiprazole manufacturer or Brexpiprazole supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Brexpiprazole manufacturer or Brexpiprazole supplier.
PharmaCompass also assists you with knowing the Brexpiprazole API Price utilized in the formulation of products. Brexpiprazole API Price is not always fixed or binding as the Brexpiprazole Price is obtained through a variety of data sources. The Brexpiprazole Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A REXULTI manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of REXULTI, including repackagers and relabelers. The FDA regulates REXULTI manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. REXULTI API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of REXULTI manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A REXULTI supplier is an individual or a company that provides REXULTI active pharmaceutical ingredient (API) or REXULTI finished formulations upon request. The REXULTI suppliers may include REXULTI API manufacturers, exporters, distributors and traders.
click here to find a list of REXULTI suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A REXULTI DMF (Drug Master File) is a document detailing the whole manufacturing process of REXULTI active pharmaceutical ingredient (API) in detail. Different forms of REXULTI DMFs exist exist since differing nations have different regulations, such as REXULTI USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A REXULTI DMF submitted to regulatory agencies in the US is known as a USDMF. REXULTI USDMF includes data on REXULTI's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The REXULTI USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of REXULTI suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a REXULTI Drug Master File in Korea (REXULTI KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of REXULTI. The MFDS reviews the REXULTI KDMF as part of the drug registration process and uses the information provided in the REXULTI KDMF to evaluate the safety and efficacy of the drug.
After submitting a REXULTI KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their REXULTI API can apply through the Korea Drug Master File (KDMF).
click here to find a list of REXULTI suppliers with KDMF on PharmaCompass.
A REXULTI written confirmation (REXULTI WC) is an official document issued by a regulatory agency to a REXULTI manufacturer, verifying that the manufacturing facility of a REXULTI active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting REXULTI APIs or REXULTI finished pharmaceutical products to another nation, regulatory agencies frequently require a REXULTI WC (written confirmation) as part of the regulatory process.
click here to find a list of REXULTI suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing REXULTI as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for REXULTI API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture REXULTI as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain REXULTI and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a REXULTI NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of REXULTI suppliers with NDC on PharmaCompass.
REXULTI Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of REXULTI GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right REXULTI GMP manufacturer or REXULTI GMP API supplier for your needs.
A REXULTI CoA (Certificate of Analysis) is a formal document that attests to REXULTI's compliance with REXULTI specifications and serves as a tool for batch-level quality control.
REXULTI CoA mostly includes findings from lab analyses of a specific batch. For each REXULTI CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
REXULTI may be tested according to a variety of international standards, such as European Pharmacopoeia (REXULTI EP), REXULTI JP (Japanese Pharmacopeia) and the US Pharmacopoeia (REXULTI USP).